Skip to main content

Biologics

ACR20 - Autoinflammatory & Still's Disease Panel

Nov 24, 2020

This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.



You can listen to this podcast on SoundCloud, iTunes, Apple Car Play

Read Article

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

Nov 20, 2020

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article

Flu and Tofacitinib

Nov 19, 2020

Dr. Kathryn Dao reviews abstract L04 - Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program - at the 2020 ACR annual meeting.

Read Article
Download our 2020 TNF Inhibitor Biosimilars worksheet. https://t.co/whebbA3Ucv https://t.co/Bm5rgBPKkH
Dr. John Cush RheumNow ( View Tweet)
Nov 19, 2020
Read more on Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis by Dr. Bella Mehta ( @bella_mehta) #ACR20 https://t.co/yataL7H8X4 https://t.co/JBM8V6OX8J
Dr. John Cush RheumNow ( View Tweet)
Nov 14, 2020

ACR20 - Day 4 Report

Nov 12, 2020

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Nov 10, 2020

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K
Nov 10, 2020
#ACR20 Abstracts on #ILD Rituximab in ILD (all observational) #1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m #1051 ➡️ 50 with IPAF: >70% stable or improved at 12m #1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX #ACRambassador
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Nov 10, 2020
Summary of #ACR20 part B: - The future is bright with many trainees producing great research per Dr. Diane Karen - Belimumab (phase III) reduced proteinuria, improved renal for, and helped w/ tapering of GC in pts w/ lupus nephritis but more infect in GC group @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Nov 09, 2020
Can you give TCZ for GCA with minimal steroids? Everyone hates steroids, right? GUSTO trial: IVMP 500mg x3d +TCZ sc q1w 14/18 achieved clinical remission at 24w (but mean 11w) 13/18 relapse-free 1/18 permanent visual loss Is that tradeoff worth it? #ACR20 ABST0515 @RheumNow
David Liew drdavidliew ( View Tweet)
Nov 09, 2020
Which biologic will you use after MTX and TNF failure for RA pts? #acr20 @rheumnow
Nov 09, 2020
Amazing lecture by Dr Jane Salmon for the RRF memorial foundation to honor Dr Shaun Ruddy #ACR20 @HSpecialSurgery @RheumNow the IMPACT study - pregnancy in APS with Certolizumab Therapy https://t.co/A9U11qI7zG
Bella Mehta bella_mehta ( View Tweet)
Nov 09, 2020
#ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/3Faj64rBjd
Eric Dein ejdein1 ( View Tweet)
Nov 09, 2020
Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow

David Liew drdavidliew ( View Tweet)

Nov 09, 2020
Improvement of enthesitis US scores consistent with bDMARD initiation/change 1⃣MASEI and OMERACT scores improved at 3 mo/6mo 2⃣Associated with clinical activity outcomes @RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo
Robert B Chao, MD doctorRBC ( View Tweet)
Nov 09, 2020
RITZAREM (RTX vs AZA maintenance post RTX induction relapsing AAV) what happened post-study? After #ACR19, hope RTX confers ongoing benefit Answer: no.
David Liew drdavidliew ( View Tweet)
Nov 09, 2020
Rheum Now shares Day 3 highlights from #ACR20. https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh
Dr. John Cush RheumNow ( View Tweet)
Nov 09, 2020
RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/

Mrinalini Dey DrMiniDey ( View Tweet)

Nov 09, 2020
Fantastic session about the 2020 guidelines for management of RA!

Dr. Tina Mahajan drtinamahajan ( View Tweet)

Nov 09, 2020
SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety. Abs#2048 #ACR20 @RheumNow https://t.

Mrinalini Dey DrMiniDey ( View Tweet)

Nov 09, 2020

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Robert B Chao, MD doctorRBC ( View Tweet)
Nov 09, 2020
Conditional recommendation to add bDMARD or tsDMARD in RA pts on maximally tolerated dose of MTX over adding HCQ+SSZ (triple therapy) per draft recommendation of new ACR RA treatment guidelines. #ACR20 @RheumNow @ElaineHusniMD https://t.co/MW0fOAeK09
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Nov 09, 2020
Draft #ACR20 Rx Recs for RA: on max tolerated MTX - add bio or tsDMARD conditional recommendation over triple therapy (MTX, HCQ, SSZ). @RheumNow. https://t.co/s6fKEW8czc
Eric Dein ejdein1 ( View Tweet)
Nov 09, 2020
Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/jyjRD5aadN
Eric Dein ejdein1 ( View Tweet)
Nov 09, 2020
×